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TITLE:  Overexpression of HPV E6/E7 Oncoproteins is 
a marker of progression to cervical cancer” 
 
INTRODUCTION 
 
 
HPV E6/E7 oncoproteins initiate the development of cervical cancer. 
Their overexpression, is associated with significantly increased risk of CIN and 
cervical cancer. 
HPV-HR infection 
PERSISTENT 
 
 
DNA-HPV 
INTEGRATION 
in cellular genome 
 
 
Celullar cycle  
deregulation: 
E6/E7 
over expression 
 
 
 Inactivation of P53 Tumour suppressor gene 
 Blocking Celular Apoptosis 
 Modulation of G Protein pathway 
 Modulation of Immune System 
 Induction of telomerase activity 
 Modulation of Chromosomal Stability 
 
 
CANCER 
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So, E6/E7 MRNA oncoprotein test for early detection of cervical cancer. 
HPV E6/E7 MRNA plus LBC test from a single specimen 
Highly specific molecular test 
It has Highest positive predictive value, Correlates to disease with PPV above 
90% vs DNA testing PPV of 43% in cells for CIN2 plus 
No false negative cases as seen in LBC test 
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AIM & OBJECTIVES 
 
 
For early detection and treatment of Cancer Cervix Developing  new molecular 
diagnosis method for screening and treating the patient on the E6 gene expression. 
 
Duration of Study One year 
Study Design 
Most appropriate screening & diagnostic test for Cervical 
Cancer all sexually active women 
Sample size 50 Patients 
Inclusion criteria 
All sexually active women above 30 years 
All pap smear positive cases 
All VIA / VILI  Positive cases 
All Colposcopy Cervical biopsy  HPE report shows CIN-
I, CIN-II and CIN-III positive cases 
Exclusion criteria 
Unmarried, all sexually active women less than 20 Years  
All pap smear Negative cases 
All VIA / VILI  Negative cases 
All Colposcopy Cervical biopsy  HPE report shows 
inflammatory changes 
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Methodology 
(Materials and Methods) 
 
Setting: 
 
This study will be carried out in the Institute of Social Obstetrics, Kasturba Gandhi 
Hospital, Madras Medical College, Chennai – 3, in association with department of 
Pathology, Kasturba Gandhi Hospital, Madras Medical College, Chennai – 3. 
 
Method: 
 
Those who are  VIAVILI Positive cases, HPE report shows CINII & CIN III  
going to do this study  under colposcopy guided with the help of plastic  spatula / 
endocervical brush remove the blood material, mucus and inflammatory cells, This 
material into the liquid fixative Solution. The suspended cells are then gently 
sucked onto the filter membrane and the filter is pressed onto a glass slide to form 
a thin monolayer, and then it is stained. The liquid can also be employed to test 
HPV infection, making it a cost-effective technique. The cells wash off plastic 
device more than wooden one, and the fixation solution contains hemolytic and 
mucolytic agents. 
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Study Population 
Average age 30-45 years. Precancerous lesions occur 10-
15 years earlier. 
Coitus before the age of 18 Years. 
Multiple sexual partners. 
Delivery of the first baby before the age of 20 Years. 
Multi parity with poor birth spacing between 
pregnancies. 
Poor personal hygiene. 
Poor socioeconomic status 
Immunosuppressed individuals. 
Women with preinvasive lesions. 
COC and progestogens use over 18 year period can cause 
adenocarcinoma of the endocervix. 
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OVERVIEW OF LITERATURE 
 
 
 Major cause of cervical cancer  is human papillomavirus  which is a  
third  most common cancer in women.  
E6/E7 activities  
. 
 E6/E7 oncoproteins  degrates the cellular tumar suppressor protein 
p53 and induces  human telomerase  reverse  transcriptase  activity 
that leads to progressive cervical carcino genesis. 
 E6/E7 oncoproteins involve histone  acetylation in cell extract. 
 E6/E7 oncoprotein involve blocking the cellular apoptosis. 
 E6/E7 oncoprotein that affects the chromosomal stability. 
 E6/E7 changes the  polarity  adhesion and Gprotein modulation. 
 E6/E7 oncoprotein  become overexpressed in replication of basel and 
para basel cells of cervix. 
 E6/E7 oncoprotein promotes the cellular proliferation. 
 E6/E7 oncoprotein regulates the HTERT in Keratinocytes and 
fibroblast. 
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ANALYSIS OF STUDY 
 
 
 
 
 
 
 
Bar Chart showing: E6/E7 Expression in Pap smear Abnormality (ASCUS) 
and Control Study. 
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Bar Chart showing: E6/E7 Expression in Low Grade Lesion (CIN 1 Mild 
Dysplasia). 
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Bar Chart showing: E6/E7 Expression in High Grade Lesion (CIN2 & 3) & 
Cancer Service and Control Study. 
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MASTER CHART 
 
 
SNO. Name 
Age / 
Sex 
LMP No. VIA / VILLI 
Pap smear 
Abnormality 
E6/E7 
Expression 
in % 
1 JANAKI 23 / F 15.10.2014 Positive ASCUS 18.80% 
2 DEVI 30 / F 28.02.2015 Positive HSIL 22.80% 
3 THENMOZHI 28 / F 05.03.2015 Positive LSIL 19.40% 
4 DHANALAKSHMI 46 / F PMS Positive ASCUS 28.40% 
5 DEVIKA 57 / F PMS Positive ASCUS 30.20% 
6 SAMUTHIRAKANI 60 / F PMS Positive ASCUS 30.60% 
7 KARPAGAM 55 / F PMS Positive LSIL 28.60% 
8 JAYASEELI 45 / F 10.05.2015 Positive ASCUS 26.80% 
9 CHANDRAMMA 63 / F PMS Positive HSIL 32.80% 
10 BABY 40 / F 15.10.2014 Positive HSIL 34.20% 
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SNO
. 
Name 
Age / 
Sex 
LMP No. 
VIA / 
VILLI 
HPE (Low 
Grade 
Lesion - 
CIN1) 
E6/E7 
Expressio
n in % 
1 ARUNMOZHI 35 / F 
04.10.201
4 
Positiv
e 
CIN1 36.80% 
2 MALLIKA 45 / F 
05.06.201
4 
Positiv
e 
CIN1 34.60% 
3 LATHA 30 / F 
06.12.201
4 
Positiv
e 
CIN1 35.80% 
4 VIDHYA 38 / F 
06.08.201
4 
Positiv
e 
CIN1 30.60% 
5 GOWRI 40 / F 
05.06.201
4 
Positiv
e 
CIN1 32.40% 
6 
BHUVANESHWA
RI 
36 / F 
06.08.201
4 
Positiv
e 
CIN1 36.40% 
7 
RASIA 
SULTANNA 
45 / F 
05.05.201
4 
Positiv
e 
CIN1 28.60% 
8 SIVAKAMI 38 / F 
05.04.201
4 
Positiv
e 
CIN1 31.40% 
9 KAMATCHI 45 / F 
04.04.201
4 
Positiv
e 
CIN1 29.40% 
10 VIJAYALAKSHMI 30 / F 
05.08.201
4 
Positiv
e 
CIN1 30.10% 
11 DEVAKI 36 / F 
04.04.201
4  
Positiv
e 
CIN1 28.40% 
12 SHANTHI 45 / F 
04.06.201
4 
Positiv
e 
CIN1 29.60% 
13 POONGODI 34 / F 
06.06.201
4 
Positiv
e 
CIN1 26.80% 
14 LAKSHMI 30 / F 
05.12.201
4 
Positiv
e 
CIN1 30.10% 
15 PARIMALA 30 / F 
06.08.201
4 
Positiv
e 
CIN1 28.90% 
16 KALA 32 / F 
05.09.201
4 
Positiv
e 
CIN1 26.80% 
17 PARVATHI 46 / F 
06.09.201
4 
Positiv
e 
CIN1 29.60% 
18 JAYASUDHA 30 / F 
07.08.201
4 
Positiv
e 
CIN1 29.60% 
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19 KALAIVANI 43 / F 
05.10.201
4 
Positiv
e 
CIN1 29.80% 
20 GOKILA 63 / F PMS 
Positiv
e 
CIN1 32.60% 
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SNO
. 
Name 
Age / 
Sex 
LMP No. 
VIA / 
VILLI 
HPE (High 
Grade 
Lesion - 
CIN2 & 3) 
E6/E7 
Expressio
n in % 
1 RAJAMMAL 48 / F 
06.12.201
4 
Positiv
e 
CIN3 46.20% 
2 TAMILSELVI 48 / F PMS 
Positiv
e 
CIN2 42.80% 
3 DEVI 38 / F 
05.12.201
4 
Positiv
e 
CIN2 41.90% 
4 JEENIRA 40 / F 
05.09.201
4 
Positiv
e 
CIN2 40.80% 
5 
POONGAVANA
M 
62 / F PMS 
Positiv
e 
CIN3 46.80% 
6 KANAGI 39 / F 
05.10.201
4 
Positiv
e 
CIN2 42.80% 
7 SARASWATHI 45 / F PMS 
Positiv
e 
CIN3 48.20% 
8 ANJALAI 40 / F 
05.10.201
4 
Positiv
e 
CIN3 49.60% 
9 CHANDRA 50 / F PMS 
Positiv
e 
CIN3 46.80% 
10 NAVANEETAM 41 / F 
05.12.201
4 
Positiv
e 
CIN3 45.80% 
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SNO
. 
Name 
Age / 
Sex 
LMP No. 
VIA / 
VILLI 
HPE Cancer 
cervix 
E6/E7 
Expressio
n in % 
1 KALA 55 / F PMS 
Positiv
e 
SQ CELL CA 79.60% 
2 THIRUMANGAI 38 / F 
05.10.201
4 
Positiv
e 
SQ CELL CA 68.90% 
3 SARASAMMAL 58 / F PMS 
Positiv
e 
SQ CELL CA 73.80% 
4 DHAMAYANTI 50 / F PMS 
Positiv
e 
SQ CELL CA 76.80% 
5 PARVATHI 40 / F 
06.10.201
4 
Positiv
e 
SQ CELL CA 78.60% 
6 EASWARI 49 / F PMS 
Positiv
e 
ADENO 
CELL CA 
68.90% 
7 RATINAMMAL 40 / F 
05.08.201
4 
Positiv
e 
SQ CELL CA 65.80% 
8 ESAKKIAMMAL 50 / F PMS 
Positiv
e 
SQ CELL CA 70.10% 
9 LAKSHMI 37 / F 
05.06.201
4 
Positiv
e 
SQ CELL CA 68.90% 
10 
DHANALAKSHM
I 
44 / F 
05.08.201
4 
Positiv
e 
ADENO 
CELL CA 
65.80% 
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RESULT 
 
 
In this study deducted  the E6/E7 oncoprotein expression  positivity in high 
grade  cervical lesion  shows around 75% to 80% , low grade cervical 
lesion shows 40% to 45% and Atipical spamus cell  lesion shows  around  
20% to 25%. 
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CONCLUSION 
 
 
  This study has done in our hospital that over expression of HPV E6/E7 
ONCOPROTEIN is a marker of progression to cervical cancer. The result were 
compared based on HPE grading of lesion, ca cervix and High Grade lesion gave 70 
to 80% of expression of E6/E7 ONCOPROTEIN. According to my study there is 
earlier diagnostic / screening test for ca cervix, so identify the lesion earlier and to 
decide the modality of treatment earlier. My study findings are suggested that 
HPVE6/E7 ONCOPROTEIN expression could be  used in diagnosing high grade 
cervical lesion and predictive tool for screening  of low grade cervical lesion.  
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REVIEW OF LITERATURE 
 
 
 
Papillomavirus E6 proteins 
 
 The papillomavirus  are small DNA viruses that encode approximately 
eight genes, and require the host cell DNA replication machinery for their 
vital DNA replication. Thus papillomaviruses have evolved strategics to  
induce host cell  DNA synthesis balanced with strategics to protect the cell 
from  unscheduled replication. While the papilomavirus E1 and E2 genes 
are directly involved in vital replication by binding to and unwinding the 
origin of replication, the E6 and E7 proteins have auxiliary functions that 
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promote proliferation. As a consequence of disrupting the normal cheek 
points that regulate cell cycle entry and progression, the E6 and E7 
proteins play a key role in the oncogenic properties of human 
papillomaviruses with a high  risk of causing anogenital cancers . As  a 
consequence E6 and E7 of HPVs are invariably expressed in cervical 
cancers. This article will focus on the E6 protein and its numerous activities 
including inactivating blocking  apoptosis, activating telomerase, disrupting 
cell adhesion, polarity and epithelial differentiation, altering transcription 
and reducing immune recognition. 
 
Structure of E6 
 All papillomaviruses  encode an E6 open reading frame immediately 
downstream of the non coding region . E6 proteins are approximately 150 
amino acids containing two CX2C-X29-CX2Czinc- like fingers joined by an 
inter domain linker of 36 amino acids, flanked by short amino and car boxy 
terminal domains of variable lengths. The E7 protein contains similarly 
19 
 
spaced zinc- like finger leading to the hypothesis that the E6 and E7 genes 
may have arisen from duplication events for one of these core motifs. A 
number of papillomavirus E6 and E7 proteins have been shown to bind zinc 
through the coordination of the cysteine residues . Attempts to obtain the 
crystal structure of E6 have been plagued by the tendency of E6 to  form 
insoluble aggregates. Recently the solution structure of the C- terminal half 
of HPV 16E6 was solved by nuclear magnetic  resonance , and a model for 
the  whole protein was proposed. The two zinc finger domains face each 
other symmetrically in a pseudodimeric fashion with the  inter domain 
forming  a helix that contributes to the rigidity of the two domains. Each 
domain consists of a three slandered beta sheet and two short helices. The 
N and C terminal domains are of variable lengths and sequences. The 
proposed structure indicated that many of the mutations that have been 
made to map functions of  E6 likely disrupted the overall structure, rather 
than specific protein- protein interactions. 
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 Although E6 may dimerize at high salt and protein concentrations, it 
is thought to be monomeric at physiologic  conditions. It has been difficult 
to study the expression of endogenous E6 proteins as they are expressed 
at low levels and few sensitive antibodies exist, however E6 is thought to 
be largely  nuclear, though  some fraction of E6 on coding residues 1-41 of 
16B6 inactivates the functions of  full- length E6, which is proposed to be 
due to  its ability to bind to the interface of the  N- and C- terminal halves of 
E6. No enzymatic activities have been reported for E6, and although the 
HR E6 proteins have been reported to bind specifically to four-way DNA  
junctions, most of the activities of E6 are thoughts to be mediated by 
protein proteins interactions.  
 
E6 binding motifs 
 The first protein that was shown to interact with E6 was E6 
associated protein, an E3 ubiquitin cascade functions to target proteins for 
proteasomal degradation by means of adding multiple ubiquitin monomers 
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to the protein  destined to be destroyed. E1 proteins activate the  ubiquitin 
monomers that are subsequently transferred by E2 conjugating  enzymes 
to an E3 ubiquitin ligase, which confers target specificity  E6AP is the 
founding member of the HECT – domain family of ubiquitin ligases, a group  
of related proteins  with homology too E6AP C- terminal domain involved in 
ubiquitination of bound substrates, and divergent N- termini that mediate 
substrate specificity  E6AP  forms a complex with both E6 and target 
proteins leading to ubiquitination of the target protein and subsequent  
proteasome mediated degradation. The most well studies E6/E6AP target 
is the tumor suppressor  though other proteins are also targeted by this 
complex. Numerous  studies  have identified residues of the E6 protein that 
diminishes binding to E6AP, but  recently most of these mutations have 
been predicted to disrupt the global integrity of E6. Moreover, mutations of 
numerous surface exposed residues of E6  did not eliminate  its  binding to 
E6AP. However, the motif on E6AP that binds E6 has been  extensively  
characterized  and is referred to an  LXXLL motif A number of other  
22 
 
proteins also bind to  E6 by way of LXXLL motif including ERC-55, IRF3, 
PAXILLIN AND TUBERIN . These motifs  are leucine rich amphipathic 
helices  with limited substitution of hydrophobic residues for leucines and at 
least one negative charge  in an X position. The sequence of E6AP that 
interacts with E6 is ELQULLGE Bending to  proteins with an LXXLL motif is 
a conserved property  of the proteins of n numerous papillomaviruses,  as 
E6AP binds to both high and low risk genus alpha HPV’s at least some 
genus beta HPV’s and bovine papillomanvirus  type 1. 
 
 HR HPV E6 proteins all have a motif designated as XT/SXV at  their  
C-tennini. This motif on the E6 protein mediates binding to specific domains 
on cellular proteins known as PDZ proteins PDZ domains are 
approximately 90 amino acid stretches found in a wide variety of  proteins  
and are  named after the first letters of three proteins which were first 
discovered to share the domain, post synaptic density protein , Drosophila 
disc large tumor  suppressor  and zoniula occludents –I protein. Among the 
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PDZ  proteins reported to bind E6 are  human homologs of  bscriib, a 
homolog  of the  Drosophilla scribble protein Hutibregate. Membrane 
Associated Guanylate kinase homology proteins with an Inverted doimain 
structure. MUPPI, a multi PDZ protein and PTPN3, a membrane associated  
tyrosine phosphatase. Mutational analyses have  demonstrated the 
importance of the XS/TV motif in binding, but it is possible that other 
residues of E6 also bind and confer specificity for which PDZ proteins and 
which PDZ domains are bound. The concurrent binding of E6 To E6AP and 
PDZ proteins can target PDZ proteins for degradation, though other 
ubiquitin ligases have  also been implicated. 
 
 Other proteins such as p53, Bak, p300/CBP, hADA3, nfxi, Gps2, 
FADD, and procaspase 8 have been reported to bind various E6 proteins, 
but they lack both LXXLL and PDZ domains .They may bind to E6 through 
as yet underfined motifs, or indirectly through binding to E6AP or other E6 
associated proteins. 
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INACTIVATION OF p53 
 One of the most well studied interacting proteins of E6 is the p53 
suppressor, a DNA site specific transcription factor, and one of the key 
signaling coordinators in the cell following genotoxide or cytotoxie stress. 
Normally present in low levels and transcriptionally inactive, cellular 
damage triggers an increase in p53 protein levels and activation via post 
translational modifications. Once activated, p53 functions to initiate 
pathways  for DNA repair, cell cycle arrest and/ or apoptosis, based upon 
the type and extent of damage. The importance of p53 in orchestrating the 
cellular response to cytotoxie agents is exemplified by the observation that 
approximately one-half of all human cancers harbor mutations in the p53 
gene. These mutations impair the ability of p53 to trigger the appropriate 
signaling pathways to  repair the damage or trigger cell death in cases 
where the damage is beyond repair. This in turn allows for replication of 
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damaged DNA, and survival of cells with deleterious mutations that would  
normally be  eliminated. 
 
 Importantly, in addition to genotoxic  and cytotoxic damage, p53 is 
also activated upon improper stimulation of DNA  synthesis, such as that 
induced by HPV infection. Both HR  and LRHPVs infect cells in the basal 
layer of the epithelium, however viral replication occurs only in 
differentiating cells- which would have normally exited the cell cycle  and 
turned off their  cellular DNA synthesis machinery HPVs  must therefore 
stimulate DNA  synthesis in these cells, while  concomitantly inhibiting the 
normal cellular  response of  activating p53. Importantly, unlike most other 
cancer cell types, cervical cancers generally  harbor wild- type p53. HPVs 
have evolved  a number of mechanisms to block p53 function in the 
infected cell through  the actions  of  the  E6 oncoprotein to  this way sour 
understanding  of E6 highlights the functions of p53 in  normal cells, and 
demonstrates the mechanisms by which a regulatory checkpoint can be 
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countered during vital infection and or cancer progression via protein 
degradation , mislocalization and modification. 
 
 The principle mechanism by which HR HPVs inactivate p53  is by 
inducing its degradation through the ubiquitin proteasome pathway. 
Normally p53 protein levels are regulated by the Mdm2 E3 ubiquitin ligase. 
However Mdin2-mediated degradation of p53 is inhibited during vital 
infection and other stress conditions, allowing for stabilization of p53 
protein levels and  subsequent activation. Instead, HR HPV E6 induces p53 
degradation by forming a complex with E3 ubiqutin ligase, E6AP . 
 
 E6AP is unable to bind  and induce its degradation. Instead, E6 must 
first bind to the n terminal substrate recognition domain of e6ap before p53 
can be bound and  ubiquitnated. Both  HR  and LR HPV E6  proteins have 
been shown to interact with p53 however they differ  with respect to the 
domains of p53 with which  they interact. While  both HR and LR E6 
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proteins cab bind to the p53 C- terminus, only HR E6 proteins are capable 
of binding to the core region of p53. It is this binding of the core region that 
is required for p53 degradation by HR E6. 
 
 Although stimulation of p53 degradation mediates a considerable 
block to p53 function, not all of the p53 within E6 expressing cells is 
degraded. Moreover, as mentioned above, the LR genus alpha HPV, and 
the genus beta HPV E6 proteins do not degrade p53 and therefore have 
evolved different mechanism of circumventing p53 growth suppression. In 
part, infection with these papilomaviruses may induce a p53 response less 
robustly that the HR HPVs. Additionally, some assays have shown that 
expression of both HR  and LR E6 proteins  can abolish p53 mediated 
transcriptional activity. It has been shown that E6 can mediate these effects 
through a number of mechanisms, including inhibition of p53 binding, 
aberrant p53 localization, and post translational modification of the p53 
protein. 
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 First  it has show that E6 interaction with p53 can inhibit the binding 
of p53 to its site specific DNA sequences . The level of  inhibition was 
found to correlate with the affinity that each E6 protein has for p53 thus 
16E6 shows the highest level of site specific binding inhibition, 31E6 and 
18E6 show intermediate levels  of inhibition, and 11E6 shows the least, 
albeit still detectable  inhibitory effect. Moreover, it was later shown that E6 
association with p53 can induce a  conformational change in the p53 
protein, which in turn leads to an inhibition of p53 binding to DNA, or a 
dissociation between p53  DNA complexes that have already been formed . 
Importantly, these inhibitory effects were shown to correlate with the ability 
of different E6 proteins to inhibit p53 transactivation, and were shown to be 
independent of  E6/E6AP – mediated p53 degradation. 
 
 The second proposed mechanism by which E6 my be able to inhibit 
p53 signaling independent of protein degradation is by means of 
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sequestration of p53 in the cytoplasm. This has been hypothesized to be a 
result of either masking of the nuclear localization signal on the p53 
terminus due to E6 binding of p53 or an enhancement of p53 nuclear 
export. As both HR and LR E6 proteins are able to bind to the C- terminus 
of p53 The second proposed mechanism by which E6 my be able to inhibit 
p53 signaling independent of protein degradation is by means of 
sequestration of p53 in the cytoplasm. This has been hypothesized to be a 
result of either masking of the nuclear localization signal on the p53 
terminus due to E6 binding of p53 or an enhancement of p53 nuclear 
export. As both HR and LR E6 proteins are able to bind to the C- terminus 
of p53  masking the p-53NLS is an attractive possibility. Evidence for E-6 
mediated mislocalization of p53 NLS is an attractive possibility. Evidence 
for E6- mediated mislocation of p53 has been demonstrated from 
experiments using cervical cell lines in which E6 mediated p53 degradation 
was blocked in these cells, even though p53 levels returned to normal, 
correct nuclear localization of p53 was perturbed. 
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 The third mechanism employed by E6 to inhibit p53 activity is its 
abrogation of the transactivation  of p53 responsive genes via interaction 
with either the  CBP/p300 histone acetylinaferases. Following DNA damage 
p300 is known to acetylate p53, thus enhancing its ability to bind to specific 
DNA sequences in the promoters of p53 responsive genes, and in turn up 
regulating  their transcription. The E6 proteins have been  shown to bind to 
p300, and this interaction inhibits p53 acetylation at p300 dependent sites, 
leading to decreased expression from a p53 responsive luciferase reporter. 
Both HR  and LR E6 proteins have been shown to bind to p300, although 
the HR E6  proteins appear to bind with  a higher affinity In-vivo studies 
have reported that only the HR E6 proteins prevent p300 transactivation of 
p53 responsive genes . However  an in-vitro analysis using chromationized 
templates demonstrated that LR HPV 11E6 was also capable of inhibiting 
p53 transactivation. This study also demonstrated that while E6 mutants 
deficient in E6AP binding were capable of inhibiting p53 mutants defective 
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in binding to either p53 or p300 were unable to elicit this response. Thus a 
complex between E6, p53 and p300 appears to be required to block 
transactivation. 
 
 Similarly, HR E6 proteins are also able to block p53 activation by 
interacting with another histone  acetyltransferase, HADA3 . HADA3 is the 
human homolog of   the yeast transcriptional activator  y,ADA3, which 
functions as an essential component of the  ADA transcriptional co 
activator complex. However, unlike with p300, E6  interaction with hADA3  
results in hADA3 degradation . This degradation has been shown to 
abrogate both p53 and retinoic X receptor alpha mediated  transactivation. 
 
 Finally, recent evidence suggests that E6 may also inhibit p53 
activation by blocking the p14/ARF pathway following most cellular 
stresses p53 is activated due to cellular signals that prevent its interaction 
with and  degradation by Mdm2. However p53 can also be activated during 
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oncogenenic stress by a mechanism involving direct inhibition of Mdm2 
ubiquitin ligase  activity through its association with ARF . 16 E6 has been 
shown to inhibit p14/ARF dependent activation of p53 without inactivation 
of the p53 dependent DNA damage response, and  in a manner that is not 
dependent  on E6- mediated p53 degradation. Interestingly, one 
mechanism by which this has been proposed to be facilitated is through the 
degradation of hADA3. 
 
Modulation of G-Protein signaling 
  As described above, E6 is able to modulate transcription of p53-dependent 
genes either by degradation of p53 or via interaction with the p300 and hADA3 
transactivators. In addition, yeast two-hybrid experiments from other cellular 
signaling pathways as well, highlighting the ability of the E6 oncoprotein to act as 
a diverse modulator of host cell signaling. With respect to G-protein signaling. E6 
has been shown to interact with three different proteins. First, Hr E6 was shown 
to bind and degrade a novelprotein termed E6-targeted proteins 1 in an E6AP 
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dependent manner. E6TP1 has homology to GTPase activating proteins (GAPs) for 
Rap, and recent experiments demonstrated that E6TP1 does indeed harbor GAP 
activity for Rap 1 and Rap 2, Importantly, E6 mediated degradation of E6TP1 
enhances the GTP-loading of RAP, thus supporting a role for the RAP small G-
protein pathway in E6-mediated oncogenesis. Another protein with GAP activity, 
tuberin, was also shown to be bound and degraded by E6. Tuber in functions in 
the harmatin-tuberin complex, which exhibits GAP activity toward the small G-
protein Rheb, and the complex is a critical negative regulator of m TOR signaling 
(reviewed in Huang and Manning, 2008). As this pathway is an important 
mediator of cell growth, it highlights yet another mechanism by which E6 can 
modulate the regulation of such processes. Finally, E6 from both HR and LRHPVs 
was shown to bind and degrade Gps2. Gps2 is involved in suppressing G-protein 
mediated signaling pathways, C-Jun N-terminal kinase activity, and known to 
stimulate transcriptional activation by the BPV1 E2 protein. As seen with BPV, 
Gps2 was found to stimulate transcription from HPV promoters. Moreover, HR 
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E6-mediated degradation of Gps2 was shown to suppress this transactivation of 
the HPV early promoter. As Gps2 is known to interact with an positively regulate 
p300, the implications of Gps2 degradation may extend beyond that of 
transcriptional control of HPV encoded genes, however this remains to be 
determined. 
 
Modulation of Immune Recognition 
  E6 has also been shown to modulate transcription of genes whose protein 
products are involved in innate immunity. HR E6 has been shown to interact with 
two proteins that are part of the innate immune response to viral infection; 
Interferon regulatory factor-3 and Toll-like receptor 9, IRF-3 becomes activated by 
dsRNA or viral infection, and this activation leads to transcription of Interferon-B. 
16E6 interaction with IRF-E has been shown to inhibit its transactivation ability, 
and thus prevents the induction of IFN-B following viral infection. TLR9 becomes 
activated by viral or bacterial dsDNA derived CpG motifs, and induces cytokine 
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production as a means to defend the cell against the invading organism. 
Exogenous expression of 16E6/E7 has been shown to inhibit TLR9 transcription, 
leading to a functional loss of TLR9 signaling pathways within the cell. Similar 
results were seen in the HPV 16 positive cervical carcinoma cell lines CaSki, SiHa 
and HeL-a, demonstrating that this may indeed contribute to HPV-mediated 
carcinogenesis. 
 
Blocking apoptosis 
  One of the main consequences of E6 degrading or blocking p53 function is 
to inhibit apoptotic signaling that would otherwise eliminate the HPV infected 
cell. However, p53 independent apoptotic signals can also be employed to 
eliminate abnormal cells, and E6 has been shown to block apoptosis in cells and 
mice lacking p53. There are two major apoptotic pathways that can be triggered 
by different stresses – the extrinsic pathway, and the intrinsic pathway. 
Interestingly, the E6 protein has been shown to disrupt both pathways to 
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facilitate a cytoprotective environment and prevent cell death, thus highlighting 
the critical signaling events that a cell undergoes following exogenous or 
endogenous stress. 
 
 The extrinsic apoptotic signaling pathway can be induced during viral infection as 
part of the host response, and is triggered by extracellular signals that induce the 
activation of “death receptors” on the cell surface. These receptors are members 
of the tumor necrosis factor receptor family and include TNF receptor 1, Fast 
CD95 and the TNF-related apoptosis inducing legend receptors DR-4 and DR-5. 
Upon binding to their cognate legend, these receptors trimerize and recruit 
adapter molecules such FADD, TRADD and initiator caspases such as caspase-8 
and caspasc-10 to their cytoplasmic death domains, thus forming the death 
inducing signaling complex. The DISC is involved in activating caspase 8, which in 
turn cleaves and activates downstream executioner caspases. The executioner 
37 
 
caspases target and cleave downstream substrates such as poly polymerase and 
Lamin B. 
 
  E6 has been shown to inhibit extrinsic apoptotic signaling at each of the 
early stages, by interacting with TNFR-1, FADD and caspase-8, 16E6 was shown to 
directly bind to the death receptor TNFR-1, an interaction that inhibited TNFR-1 
association with the TNFR1-associated death domain adapter molecule, and 
blocked TNFR-1 DD mediated apoptosis. Importantly, 16E6 has also been shown 
to block apoptosis normally triggered by TNF, the cognate legend for TNFR-1. In 
addition to the TNF pathway, it has also been shown that 16E6 is capable of 
inhibiting apoptosis stimulated by both the FAS and the TRAIL pathways. This 
inhibition is mediated by E6 binging to and degradation of both the FADD adapter 
protein and the effector caspase, caspase-8. As FADD and caspase-8 are key 
components to apoptotic signaling through all of the death receptors, this 
mechanism of cytoprotection demonstrates how the E6 oncoprotein is able to 
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exploit one or two proteins as a means to block multiple signaling pathways. 
Importantly, these effects were all seen using the HR 16E6 oncoprotein, and it is 
unknown whether LR or genus beta HPVE6 proteins function in a similar manner 
with respect to blocking extrinsic apoptotic pathways. As the binding of FADD is 
not dependent on the conserved PDZ domain of HR E6, but rather a novel 
domain, it is possible that other E6 proteins may inhibit these extrinsic pathways. 
 
  The intrinsic apoptotic pathway is involved in sensing apoptotic signals that 
originate from within the cell, such as DNA damage, oxidative stress, starvation 
and those mediated by chemotherapeutic drugs. These stresses activate a 
number of pathways that converge on the mitochondria, which acts as a hub to 
sese to balance of pro- and anti-apoptotic signals and facilitate downstream 
apoptotic signaling when this balance is upset. When the cell senses intrinsic 
stress, pro-apoptotic BH3- only proteins become activated and abrogate the 
function of anti-apoptotic proteins. This allows for the formation of pores in the 
39 
 
mitochondrial membrane comprised of prop-apoptotic Bax or Bak, and 
subsequent release of mitochondrial inner membrane proteins such as 
cytochrome c, apoptosis inducing factor, endonuclease G, Smac/Diablo and 
Htr/Omi. These mitochondrial proteins form the “apoptosome”, an apoptotic 
signaling complex that, like the DISC from the extrinsic pathway, result in the 
cleavage of caspase 3 and caspase 7, and ultimately cell death. 
 
  The E6 oncoproteins from both HR and LR HPVs have been found to block 
intrinsic apoptotic signaling primarily by interacting with only one protein – BAK. 
Both HR and LR E6proteins from genus alpha and beta HPVs have been shown to 
bind BAK, and induce its proteasomal-dependent degradation. While E6AP has 
been shown to play a role in BAK degradation, it has also been proposed that this 
may not be a universal mechanism for all of the HPV types, thus the involvement 
of other E3 ubiquitin ligases in this process is an area of interest. Whether BAK 
degradation is constitutive or induced following cell stress is also a topic of 
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controversy. Recent evidence has shown that BAK degradation is not constitutive, 
but rather occurs only after apoptotic signals have been initiated, indicating that a 
BAK conformational change and/or dissociation from its anti-apoptotic partner 
MCL-1 may be necessary for its interaction with E6 and E6AP. Other studies have 
found constitutively lower levels of total BAK protein in E6 expressing cells. 
Regardless of whether BAK degradation is constitutive or induced, the overall 
effect has been shown to be a block the release of cytochrome c, AIF and Omi 
from the mitochondria, preservation of mitochondrial integrity, and disruption of 
the cleavage of effector caspases. A final area of controversy surrounds the ability 
of E6 to perturb increase in the anti-apoptotic Bc1-2 protein. Another group 
demonstrated that 5E6 and 8E6 expression leads to a decrease in the levels of Bar 
protein expression. A third study examined the levels of NOXA, Puma, Bc1-xL, 
Mc1-1, Bc1-2 and BAX, and found none of these intrinsic apoptotic signaling 
proteins to be perturbed in E6-expressing cells. 
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  Importantly the extrinsic and intrinsic pathways are not isolated. Caspase 8 
can be activated during intrinsic apoptotic signaling via an amplification loop 
mediated by caspases 3 and 7. Likewise, mitochondrial signaling can be triggered 
during activation of the extrinsic cascade, via caspase 8 mediated cleavage of the 
BH3-only protein Bid. These mechanisms are through to help amplify apoptotic 
signaling once signals have been detected. Thus, by E6 targeting both intrinsic and 
extrinsic signaling, it not only protects an infected cell from multiple apoptotic 
stimuli, but also protects the cell from cross activation between these two 
pathways. Moreover, E6 has been shown to interact with proteins that are 
involved in apoptotic signaling at the crossroads where the intrinsic and extrinsic 
pathways join, downstream of the effecter caspases. HPV 16E6 has been shown 
to upregulate the expression of two inhibitor of apoptosis proteins, c-IAP2 and 
suvivin. IAPs are proteins that can bind to and inactivate the executioner 
caspases, caspase-e and caspase-7. c-IAP2 up regulation appears to be due to E6 
mediated activation of NF kappa B, a well known anti-apoptotic signaling 
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molecule. As NF kappa B has other well known cytoprotective effects, it is 
possible that other NF kappa B responsive proteins play a role in E6 mediated 
cytoprotection as well. Finally, 16E6 dependent manner. However other studies 
have reported increased levels of c-MYC in E6 expressing cells or no change in the 
level of c-MYC, thus the overall role that C-MYC may play in E6 mediated 
cytoprotection is uncertain. 
 
Induction of telomerase activity 
  Expression of HR HPV E6 protein in concert with HR HPV E7 protein can 
immortalize epithelial cells in culture and one critical cellular target is telomerase. 
Understanding how E6 affects telomerase shines a spotlight on a critical target for 
oncogenic progression and avoidance of cellular senescence. 
 
  As linear DNA is replicated in each cell division, approximately 150-200 
nucleotides at the 3’ end of chromosomes is lost due to the directional 
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amplification of DNA. To avoid losing critical genetic information on chromosomes 
and to prevent recombination at the termini, their ends are capped with 
repetitive telomeric DNA approximately 10-12 kilo bases in length and proteins 
collectively named sheltering. The protection of genetic material within 
chromosomes is important, as is the folding of telomeric DNA into a T-loop to 
avoid DNA damage signals and senescence or apoptosis signals. As telomeres 
shorten with each cell division, the age of a cell is clearly marked in time. When 
telomeres become critically shortened, cells are signaled to senesce; if they do 
not, there can be catastrophic DNA damage, including anaphase bridges and 
double strand DNA breaks. 
 
  Telomerase is a ribonucleoprotein that extends to telomeric ends of linear 
chromosomes in eukaryotes. Normally quiescent in somatic cells, telomerase is 
active in stem cells and during embryonic development. The RNA component of 
telomerase, TERC, is the template for the repetitive DNA in telomeres, TTAGGG in 
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humans. Dyskerin is an additional key protein subunit of telomerase, and HTERT is 
the catalytic subunit of telomerase. The expression level of HTERT is 
proportionate to the enzymatic activity of telomerase in cells, and in the majority 
of immortalized cells and cancers HTERT is detected. If telomerase is not active in 
immortalized cells or in cancers, telomeric DNA is extended using the alternative 
lengthening of telomeres pathway of homologous end joining. So, the protection 
of telomeric DNA to avoid signals of cellular senescence or catastrophic 
chromosomal damage is key to cellular dysregulation in cancers and must be 
controlled in normal, differentiated somatic cells. 
 
  In 1996 it was found that HR HPV E6 protein could activate telomerase in 
epithelial cells and less than ten later it was found that E6AP was critical for 
HTERT regulation by E6. HR E6 binds the endogenous E6AP protein and utilizes it 
in its activation of HTERT and telomerase. Knockdown of E6AP decreases the 
telomerase activity triggered by HPV 16E6, as well as genus beta HPV E6 types 38 
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and 8. In one study, mutants of PV 16E6 that cannot bind E6AP, when expressed 
in epithelial cells, were also unable to induce HTERT transcription, however, 
another study using E6 mutants did not find a requirement for E6AP in HTERT 
induction. 
 
  The oncogene c-MYC has been shown to activate HTERT transcription. The 
heterodimer c-MYC/Max binds two E-box sequences in the core proximal 
promoter of HTERT. The HR E6 protein required the two proximal E-box 
sequences to activate HTERT, as mutations in the E-box sequence blunts the 
activation of HTERT by E6 in luciferase assays. In vivo, E6 c-MYC, and E6AP are 
found at the HTERT promoter and although there is no strong evidence for 
significant total increases in protein levels of C_MYC nor differences in c-MYC 
levels at the HTERT promoter with E6 expression in Keratinocytes, c-MYC is 
important in HPV associated and non-HPV associated activation of HTERT, The 
interaction of HPV E6 with E6AP and c-MYC helps define the role of c-MYC in 
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HTERT activation in keratinocytes and differentiate the regulation of HTERT in 
keratinovytes and fibroblasts. 
 
  Upstream stimulatory factors also bind to E-box sites and disrupt binding of 
c-MYC/Max. Although USFs bind with less affinity to E-boxes, USF1 and USF2 are 
more abundant than c-MYC/Max and can compete for these sites. USF1 and USF2 
have been reported to occupy the HTERT remoter in keratinocytes, and with E6 
expression the amount of USF1 and USF 2 at the promoter is reduced. 
 
  GC-rich sequences are founds throughout the HTERT promoter, and Sp1 
binds to five GC-rich sites flanked by the two critical E-boxes. Mutations within 
these sites reduce the basal expression detected from the HTERT promoter, and 
the increases in HTERT promoter driven expression are seen in HPV E6 cells. 
Therefore, the effects of HPV E6 on HTERT expression point to an additional 
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transcriptional activator of HTERT found commonly in keratinocytes and recruited 
by HPV E6 for its activation of telomerase. 
 
  Transcriptional activators and RNA polymerases all require access to their 
DNA sequences, like c-MYC/Max to their E-boxes and Sp1 to its GC-rich sites. 
Acetylation of histones on which DNA is wound opens the structure of chromatin 
to these proteins. HPV E6 induces histone acetylation at the HTERT promoter, and 
this acetylation depends on E6AP. With continued passage of HPV E6 cells in 
culture, the acetylation of the HTERT promoter increases, and knockdown of E6AP 
reduces this acetylation. Thus HPV E6 with E6AP adds to the evidence of direct 
transcriptional gene regulation through transcriptional activators or repressors 
binding to cis elements in promoters, as well as epigenetic regulation of gene 
expression, all through its effect on HTERT. 
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  As E6/E6AP targets p53 for polyubiquitination and degradation, it also was 
hypthesized that E6/E6AP may target a yet unknown transcriptional repressor at 
the HTERT promoter for polyubiquitination and degradation. In 2004, NFx1-91 
was identified as a transcriptional repressor of HTERT in a yeast two hybrid screen 
with HPV 16E6 and E6AP. NFX1, or nuclear factor binds to the X1 box, was 
originally identified as an MHC class II gene repressor. Two splice variant isoforms 
are expressed in epithelial cells, with NFX1-91 referring to its kilodalton mass. In 
keratinocytes, NFX1-91 binds to a X1 box sequence in the HTERT promoter, 
recruiting to transcriptional co-repressor mSin3A and histone deacetylase activity 
to shut off HTERT expression. The protein-protein interaction of NFX1-91 with the 
heterodimer HPV E6/E6AP identified a new endogenous transcriptional repressor 
of HTERT important in the regulation of telomerase in epithelial cells. 
 
  Like p53, NFX1-91 is polyubiquitinated and targeted for degradation by 
16E6/E6AP. The level of NFX1-91 in HPV 16E6 expressing cells is reduced, as is its 
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occupancy at the HTERT promoter. Concomitantly, histone acetylation increases 
at the HTERT promoter, though the acetylase has yet to be identified. 
 
  To fully induce HTERT expression and telomerase activity in kertinocytes, 
HPV E6/E6AP requires expression of NFX1-123, the other splice variant of NFX1. 
Unlike NFX1-91, NFX1-123 augments HTERT promoter driven expression by HPV 
E6/E6AP. NFX1-123 interacts with cytoplasmic poly (A) binding proteins, which 
bind to the poly (A) tail of mRNA and increase protein expression through nuclear-
to-cytoplasmic transcript shuttling, translational machinery recruitment, and 
mRNA stabilization. The PAM2 of NFX1-123 is required for the interaction with 
cytoplasmic poly(A) binding proteins, and this motif is critical for the increase in 
HTERT expression when NFX1-123 is over expressed in E6 expressing 
keratinocytes. This interaction between HPV E6/E6AP, NFX1-123, and cytoplasmic 
poly(A) binding proteins, hints at additional evidence of HTERT regulation beyond 
transcriptional regulation. 
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Mediating Chromosome Stability 
  In addition to increasing the expression of HTERT, E6 also interacts with 
other proteins involved in maintaining chromosomal stability within the HPV 
infected cell. First, E6 from both HR and LR HPVs have been shown to interact 
with the human mini chromosome maintenance 7 protein, although binding by 
HR E6 proteins appears to be stronger than that by LR E6 proteins. Moreover, 
18E6 was shown to mediate MCM7 degradation via E6AP and proteasomal 
involvement. As MCM7 is involved in licensing DNA replication to ensure a single 
round of DNA replication per cell cycle, it is thought that E6 interaction with 
and/or degradation of MCM7 may lead to chromosomal abnormalities in HPV 
infected cells. E6 has also been shown to interact with two proteins involved in 
single strand DNA break repair – XRCC1 and O(6)-methylguanine-DNA 
methltransferase. XRCC1 was shown to be bound by HPV 1, 8 and 16E6, and this 
interaction reduced the ability of XRCC1 to repair meth1 methane sulfate induced 
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DNA damage. E6 interaction with MGMT induces its proteasomal-mediated 
degradation via E6AP, which has been hypothesized to sensitize HPV-infected 
cells to alkylating DNA damage. Finally, HR E6 mediated p53 loss inactivates the 
G1 checkpoint. Prolonged proliferation in the absence of p53 can lead to the loss 
of the G2 checkpoint, which can result in aneuploidy. Together, these interactions 
may lead to increased genomic instability and accelerate the progression to 
carcinogenesis. 
 
Disrupting cell adhesion, polarity and epithelial differentiation 
  Basal cells of squamousepithlium attach to the extracellular metric (ECM) of 
the basement membrane and receive signals allowing their proliferation. Once 
daughter cells detach from the basement membrane and migrate to suprabasal 
layers, proliferative signals cease and markers of epithelial differentiation are 
expressed. The establishment of cell ECM adhesion, cell, cell contact, cytoskeletal 
organization and apicobasal polarity of epithelial cells is tightly regulated to 
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assure regulated proliferation and differentiation. E6 proteins, particularly of HR 
HPVs, disrupt many of these processes to allow proliferation of differentiated 
cells and inhibition of terminal differential to support viral replication. 
 
  Both PAXILLIN and ZYXIN are focal adhesion molecules that are involved in 
tethering the cellular cytoskelton to the ECM and transmitting signals along the 
actin network from the ECM to the nucleus. E6 from diverse papilomaviruses have 
been shown to bind to these proteins resulting in the disruption of action fibers 
and a failure to maintain proper cell structure. 
 
  HSCRIB, a PDZ domain containing protein, is also involved in epithelial tight 
junctions, mediating the adhesion of basal cells to the ECM. It functions as a 
tumor suppressor that negatively regulates proliferation. HR HPV E6 proteins bind 
to HSCRIB, and at in some cell types have been shown to mediate its degradation. 
Similarly, HDLG is a PDZ domain containing protein involved in epithelial tight 
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junctions, cell, cell junctions and epithelial polarity, functioning as a tumor 
suppressor. HDLG was the first PDZ protein shown to bind to HR E6 proteins. The 
MAGI proteins and MUPP1 also play role in maintain epithelial cell junctions, 
negatively regulating cell proliferation and in signal transduction from the cell 
membrane. Likewise they bind HR HPV E6 proteins and disrupt regulation of 
epithelial proliferation. Recently it has been shown that PTPN3, a membrane-
bound tyrosine phosphatase that regulates growth factor receptors is also a PDZ 
protein that binds and is disrupted by E6. 
 
  Whether HR HPV E6 proteins bind and target all those PDZ proteins for 
degradation in vivo is controversia;. When the HPV 31 genome was transfected 
into keratinovytes Western analysis did not reveal any significant changes in the 
levels of PDZ proteins and in organotypic raft cultures, immunohistochemical 
analysis failed to identify substantial changes in the differentiation-dependent 
membrane localization of HDLG proteins. Instead, deletion or mutation of PDZ 
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domain-binding motif of E6 impaired the growth rate of cell lines harboring the 
mutant genomes and reduced the viral copy number compared to cells 
transfected with wild-type genomes. The results suggested that binding of E6 to 
PDZ proteins modulates the early viral functions such as proliferation and 
maintenance of the viral copy number in undifferentiated cells. Additionally, 
studies that have investigated the mechanism of degradation of the PDZ proteins 
in-vitro have reached opposite conclusions as to whether E6AP is the ubiquitin 
ligase that promotes proteosomal degradation. 
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PROFORMA 
 
 
1. Case study No.:      Date: 
IP/OP No.: 
2. Patient Name:      Age: 
3. Address: 
4. Education: Yes/No   Specification: 
5. Working women: Yes / No 
If Yes, state the occupation: 
If No, state the mode of income for family: 
6. Married : Yes / No   Age when married :  
7. No. of pregnancies : 
8. Type of testing undergone : HPV testing / Cytologic testing / VIA 
9. Treatment given already : Chemotherapy / Radiotherapy / None 
10. Clinical CIN grade : I / II / III / IV / could not be assessed 
11. Cell differentiation : Well differentiated / moderately differentiated / poorly 
differentiated / undifferentiated / unknown 
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12. Samples : Blood / Tumour tissue / Normal tissue 
13. Abnormal findings / symptoms : 
14. Sample collected by: 
15. Consent from patient: 
 
 
          Signature 
 
INFORMATION TO PARTICIPANTS 
 
Title:    Over expression of HPV E6/E7 Oncoprotenins in a marker   
              of progression to   cervical cancer” 
 
Principal Investigator:   Dr. D. KAMALI, MBBS,DGO 
    Post Graduate in M.S., Obstetrics and Gynaecology 
    Institute of Social Obstetrics 
    Kasturba Gandhi Hospital 
    Madras Medical College 
    Chennai - 600003 
 
Name of Participant: 
 
Site:    Institute of Social Obstetries 
 Kasturba Gandhi Hospital 
 Madras Medical College 
 Chennai – 600003 
 
You are invited to take part in this research/ study/procedures/tests. The 
information in this document is meant to help you decide whether or not to take part. 
Please feel free to ask if you have any queries or concerns. 
 
What is the purpose of research? 
 
Cervical Cancer  is  a common   disorder characterized by_ Bleeding per vaginum/ 
white discharge PV      These symptoms may last for  2 to 3 years.. We want to test the 
efficacy and safety of a new lab test  in this disease/condition.  
 
We have obtained permission from the Institutional Ethics Committee.  
 
The study design 
 
All patients in the study will be divided into two  groups (if there are groups). You 
will be assigned  to either of the  groups. [Explain briefly].   
 
Study Procedures 
 
The study involves evaluation of genes/ lab test ) for which we will be monitoring 
your  symptoms  The planned scheduled visits involve visits at three to six months at 
once  depends upon  on HPE report or cervi plus report and after your initial visit. You 
will be required to visit the hospital 3 number of times during the study.  
 
 At each visit, the study physician will examine you. Some [blood / urine / other] 
tests will be carried out at each visit. [… … ml of blood will be collected at each visit. 
Blood collection involves prick with a needle and syringe.] These tests are essential to 
monitor your condition, and to assess the safety and efficacy of the treatment given to 
you. 
 
In addition, if you notice any physical or mental change(s), you must contact the 
persons listed at the end of the document. [You will be required to return unused study 
medicines when you report for your scheduled visits. This will enable correct 
assessment of the study results. (for drug studies)] 
 
You may have to come to the hospital (study site) for examination and investigations 
apart from your  scheduled visits, if required. (In sample collection studies eg 
tissues/blood etc and analysis of gene studies - you must give information on the study 
and purpose of the tests)   
 
Women of childbearing potential 
 
You may t participate if you are pregnant, breastfeeding a child, or if you are of 
childbearing  potential and not practicing effective methods of contraception (for 
studies/procedures which may no harm to the fetus).    
 
Possible risks to you:  Nil    
 
Possible benefits to you -: Yes 
 
 The objective of screening t is to reduce the incidence and mortality from 
cerivical cancer. Even a single smear in a life time, if appropriately timed, will 
produce some benefits. If extended only to high risk group, the mortality from the 
cancer deaths will still be reduced to 60 percent.  
 
Possible benefits to other people  
The results of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefit to future patients. 
 
Confidentiality of the information obtained from you 
 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and your 
medical history). By signing this document, you will be allowing the research team 
investigators, other study personnel, sponsors, Institutional Ethics Committee and any 
person or agency required by law like the Drug Controller General of India to view your 
data, if required. 
 
The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
 
Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken care of  
and you will not loose any benefits to which you are entitled.  
 
Can you decide to stop participating in the study once you start? 
 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving any 
reasons. However, it is advisable that you talk to the research team prior to stopping the 
treatment/discontinuing of procedures etc. 
 
 
 
Signature of Investigator                                                        Signature of Participant   
Date                                                                                                     Date:   
  
 INFORMED CONSENT FORM 
 
Title:  “Over expression of HPV E6/E7 Oncoprotenins in a marker of Progression  
             to cervicalcaner” 
 
Name of the Investigator: Dr.Kamali 
  
Name of the Participant: 
                                              
Name of the Institution:  Institute of Social Obstetries 
    Kasturba Gandhi Hospital 
    Madras Medical College 
    Chennai - 600003 
 
I _____________________________ have read the information in this form (or it 
has been  read to me). I was free to ask any questions and they have been answered. I 
am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in this study. 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have informed the investigator of all the treatments I am taking or have taken in the 
past months/years   including any native (alternative) treatments.  
6. I have been advised about the risks associated with my participation in the study.* 
7. I agree to cooperate with the investigator and I will inform him /her immediately if I 
suffer unusual symptoms. *  
8. I have not participated in any research study within the past  24 month(s). *  
9. I have not donated blood within the past  6 months. . * 
10. I am aware of the fact that I can opt out of the study at any time without having to 
give any reasoned this will not affect my future treatment in this hospital. *  
11. I am also aware that the investigators may terminate my participation in the study at 
any time, for any reason, without my consent. *    
12. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Govt. agencies, and IEC if required. 
13. I understand that my identity will be kept confidential if my data are publicly 
presented.  
14. I have had my questions answered to my satisfaction.  
15. I consent voluntarily to participate in the research/study.  
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form, I attest that the information given in this 
document has been clearly explained to me and understood by me. I will be given a 
copy of this consent document. 
 
For adult participants 
 
1. Name and signature / thumb impression of the participant (or legal representative if  
     participant incompetent) 
 
    Name ___________________  Signature_________________ Date_______ 
 
 
 
2. Name and Signature of the investigator or his representative obtaining consent: 
 
    Name _____________________ Signature_________________ Date_______ 
 
For observational studies or those in which patients tissue, body fluids are collected for 
any kind of analysis, points 6,7,8,9,10,11 may be excluded in such cases.      
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